DRTS vs NVS

Novartis AG (NVS) offers the better valuation at 20.

2x trailing P/E (16. 6x forward), making it the more compelling value choice. Analysts rate Alpha Tau Medical Ltd. (DRTS) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Novartis AG (NVS) delivered a total return of +94.

4%, compared to -19. 2% for Alpha Tau Medical Ltd. (DRTS). Over 10 years, the gap is even starker: NVS returned +178. 5% versus DRTS's -22. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Novartis AG (NVS) is the lower-risk stock at 0.

42β versus Alpha Tau Medical Ltd. 's 1. 72β — meaning DRTS is approximately 306% more volatile than NVS relative to the S&P 500. On balance sheet safety, Alpha Tau Medical Ltd. (DRTS) carries a lower debt/equity ratio of 18% versus 80% for Novartis AG — giving it more financial flexibility in a downturn.

On earnings-per-share growth, the picture is similar: Novartis AG grew EPS 22.

5% year-over-year, compared to -17. 8% for Alpha Tau Medical Ltd.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Novartis AG (NVS) is the more profitable company, earning 25.

6% net margin versus 0. 0% for Alpha Tau Medical Ltd. — meaning it keeps 25. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NVS leads at 31. 2% versus 0. 0% for DRTS. At the gross margin level — before operating expenses — NVS leads at 75. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for DRTS: 52.

9% to $12. 00.

In this comparison, NVS (2.

8% yield) pays a dividend. DRTS does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Novartis AG (NVS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

42), 2. 8% yield, +178. 5% 10Y return). Alpha Tau Medical Ltd. (DRTS) carries a higher beta of 1. 72 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (NVS: +178. 5%, DRTS: -22. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

NVS pays a dividend while DRTS does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.